PainPhase 3PainNCT00680472
HKT-500 in Adult Patients With Shoulder Pain
A Phase 3 study testing HKT-500 Ketoprofen Topical Patch in people with Pain, run by Hisamitsu Pharmaceutical Co., Inc. at 35 sites in United States.
Trial summary
The objective of this study is to determine the efficacy of HKT-500 in subjects with acute shoulder pain Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Pain
- What is being tested?
- HKT-500 Ketoprofen Topical Patch
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 368 participants
- Where
- 35 sitesUnited States
- Study dates
- Apr 2008to Oct 2008
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- The subject has unilateral acute shoulder pain.
Who cannot join
- The subject is a women of childbearing potential who has a positive urine pregnancy test, or who is lactating, or who is not surgically sterile (by tubal ligation or hysterectomy), or at least 2 years postmenopausal, and has not practiced an acceptable form of birth control (defined as the use of an intrauterine device with spermicide, a barrier method with spermicide, condoms with spermicide, subdermal implant, oral contraceptives, or abstinence) for at least 2 months prior to Visit 1.
Trial locations and contacts
35 sites in 1 country.
35 sites in 1 country
United States35 sites
Hisamitsu Investigator Site
Birmingham, Alabama, 35209
Hisamitsu Investigator Site
Blue Ridge, Georgia, 30513
Hisamitsu Investigator Site
Boise, Idaho, 83702
Hisamitsu Investigator Site
Bowie, Maryland, 20716
Hisamitsu Investigator Site
Bradenton, Florida, 34209
Hisamitsu Investigator Site
Bridgewater, New Jersey, 08807
Hisamitsu Investigator Site
Bryan, Texas, 77802
Hisamitsu Investigator Site
Cary, North Carolina, 27513
Hisamitsu Investigator Site
Chiefland, Florida, 32626
Hisamitsu Investigator Site
DeLand, Florida, 32720
Hisamitsu Investigator Site
Delray Beach, Florida, 33484
Hisamitsu Investigator Site
Denver, Colorado, 80204
Hisamitsu Investigator Site
Dunedin, Florida, 34698
HIsamitsu Pharmaceutical Co., Inc.
Durham, North Carolina, 27704
Hisamitsu Investigator Site
Fargo, North Dakota, 58104
Hisamitsu Investigator Site
Fargo, North Dakota, 58108
Hisamitsu Investigator Site
Fullerton, California, 92835
Hisamitsu Investigator Site
Kalamazoo, Michigan, 49009
Hisamitsu Investigator Site
Longwood, Florida, 32779
Hisamitsu Investigator Site
New Tazewell, Tennessee, 37825
Hisamitsu Investigator Site
Newport News, Virginia, 23606
Hisamitsu Investigator Site
Oldsmar, Florida, 34677
Hisamitsu Pharmaceutical Co., Inc.
Orange City, Florida, 32763
Hisamitsu Investigator Site
Paducah, Kentucky, 42003
HIsamitsu Pharmaceutical Co., Inc.
Perrysburg, Ohio, 43551
Hisamitsu Investigator Site
Plantation, Florida, 33324
Hisamitsu Investigator Site
Raleigh, North Carolina, 27615
Hisamitsu Investigator Site
San Antonio, Texas, 78217
Hisamitsu Investigator Site
Tampa, Florida, 33603
Hisamitsu Investigator Site
Tampa, Florida, 33609
Hisamitsu Investigator Site
Tempe, Arizona, 85283
Hisamitsu Investigator Site
Toledo, Ohio, 43623
Hisamitsu Investigator Site
Washington D.C., District of Columbia, 20003
Hisamitsu Investigator Site
Wichita, Kansas, 67205
Hisamitsu Investigator Site
Zanesville, Ohio, 43701
About this study
Official title: Protocol HKT-500-US08: A Randomized, Multicenter, Double-blind, Placebo-controlled, Two-week Study to Assess the Efficacy and Safety of HKT-500 in Subjects With Acute Shoulder Pain
The objective of this study is to determine the efficacy of HKT-500 in subjects with acute shoulder pain
Read the detailed description
Randomized, double-blind, placebo-controlled, multicenter study in men and women 18 years of age or greater who have acute shoulder pain requiring analgesic treatment daily for at least 2 weeks.
- Conditions
- Pain
- Being tested
- HKT-500 Ketoprofen Topical Patch, Placebo Patch
- Keywords
- Shoulder pain, Pain, Ketoprofen, Topical Patch
- Medical subject headings
- Pain, Shoulder Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
HKT-500 Ketoprofen Topical PatchDrug
Also called Ketoprofen Topical Patch
HKT-500 Ketoprofen Topical Patch
Placebo PatchOther
Also called Sham treatment
Treatment with Placebo Patch
| Study group | Role | What they receive |
|---|---|---|
| A,1 HKT-500 Ketoprofen Topical Patch | Active comparator | A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Two-Week Study to Assess the Efficacy and Safety of HKT-500 in Subjects with Acute Shoulder Pain Receives: Drug: HKT-500 Ketoprofen Topical Patch |
| A,2 Placebo Patch | Placebo comparator | Treatment with placebo patch Receives: Other: Placebo Patch |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pain Assessment
Measured: 2 Weeks
Secondary outcomes (1)
Safety Assessment
Measured: 2 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 May 2008 (estimated)
- Study startApr 2008
- Primary completionOct 2008
- Study completionOct 2008
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PainStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 368 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hisamitsu Pharmaceutical Co., Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Kenichi Furuta, Study director, Hisamitsu Pharmaceutical Co., Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00680472
- Sponsor's protocol ID
- HKT-500-US08
- Acronym
- Pain
- Status last verified
- May 2015
- First submitted
- 16 May 2008
- Last updated
- 4 Jun 2015
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 4 Jun 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Protocol HKT-500-US08: A Randomized, Multicenter, Double-blind, Placebo-controlled, Two-week Study to Assess the Efficacy and Safety of HKT-500 in Subjects With Acute Shoulder Pain
- ClinicalTrials.gov ID
- NCT00680472
- Acronym / sponsor ID
- Pain / HKT-500-US08
- Conditions
- Pain
- Keywords
- Shoulder pain, Pain, Ketoprofen, Topical Patch
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 368 participants (actual)
- Lead sponsor
- Hisamitsu Pharmaceutical Co., Inc.Industry (pharma, biotech, devices)
- Study start
- Apr 2008
- Primary completion
- Oct 2008 (actual)
- Study completion
- Oct 2008 (actual)
- First posted
- 20 May 2008 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this study is to determine the efficacy of HKT-500 in subjects with acute shoulder pain
Detailed description
Randomized, double-blind, placebo-controlled, multicenter study in men and women 18 years of age or greater who have acute shoulder pain requiring analgesic treatment daily for at least 2 weeks.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| A,1 HKT-500 Ketoprofen Topical Patch | Active comparator | Drug: HKT-500 Ketoprofen Topical PatchA Randomized, Multicenter, Double-Blind, Placebo-Controlled, Two-Week Study to Assess the Efficacy and Safety of HKT-500 in Subjects with Acute Shoulder Pain |
| A,2 Placebo Patch | Placebo comparator | Other: Placebo PatchTreatment with placebo patch |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- The subject has unilateral acute shoulder pain.
Key exclusion criteria (1 listed)
- The subject is a women of childbearing potential who has a positive urine pregnancy test, or who is lactating, or who is not surgically sterile (by tubal ligation or hysterectomy), or at least 2 years postmenopausal, and has not practiced an acceptable form of birth control (defined as the use of an intrauterine device with spermicide, a barrier method with spermicide, condoms with spermicide, subdermal implant, oral contraceptives, or abstinence) for at least 2 months prior to Visit 1.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| HKT-500 Ketoprofen Topical PatchAlso: Ketoprofen Topical PatchHKT-500 Ketoprofen Topical Patch | Drug | A,1 HKT-500 Ketoprofen Topical Patch |
| Placebo PatchAlso: Sham treatmentTreatment with Placebo Patch | Other | A,2 Placebo Patch |
Primary outcome
Pain Assessment
Time frame: 2 Weeks
1 secondary outcome
Safety Assessment
Time frame: 2 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Jun 2015.
Related trials for Pain
Not yet recruiting
Effect of Stress Ball Use During Femoral Arterial Sheath Removal After Coronary Angiography
Femoral Arterial Sheath Removal, Stress Ball
Recruiting
Empowered Relief® for Cancer Survivors With Chronic Pain
Chronic Pain Due to Cancer, Pain Catastrophizing
RecruitingPhase 4
ESP Blocks for Posterior Spinal Fusion
Postoperative Pain
RecruitingObservational study
Pain Phenotypes in Individuals With Multiple Sclerosis
Multiple Sclerosis, Chronic Pain
Not yet recruiting
Effects of Hip Hinge Exercises on Pain, Range of Motion and Functional Disability in Non-specific Low Back Pain.
Low Back Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Kenichi Furuta study director
Hisamitsu Pharmaceutical Co., Inc.
35 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing HKT-500 Ketoprofen Topical Patch in people with Pain, run by Hisamitsu Pharmaceutical Co., Inc. at 35 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Jun 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 35 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pain Assessment (time frame: 2 Weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Jun 2015.